Video

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma (DLBCL).

Although there are data emerging from many phase 2 and 3 trials in DLBCL and other hematologic malignancies, high-risk and vulnerable patient populations are often excluded from these trials, Orellana-Noia adds. The younger, more fit patients enrolled in these trials generally do not present with central nervous system disease, HIV, prior solid organ transplant, and more, Orellana-Noia explains.

Investigators must make efforts to make clinical trial eligibility more inclusive to evaluate emerging therapies in patients who have higher-risk disease, Orellana-Noia concludes.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma